Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 721-727 , October 2009

Improved work-up procedure for the production of [18F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke

This work is dedicated to the memory of Prof. George Just.

  • Gassan Massaweh

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Esther Schirrmacher

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Christian la Fougere

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • Department of Nuclear Medicine, Ludwig-Maximilians University, Munich, Germany
    • ,
  • Miriam Kovacevic

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Carmen Wängler

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Dean Jolly

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Paul Gravel

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Andrew J. Reader

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Alexander Thiel

      Affiliations

    • Department of Neurology and Neurosurgery, McGill University, Montreal, Canada
    • Corresponding Author InformationCorresponding authors. Ralf Schirrmacher is to be contacted at Tel.: +1 514 398 1624; fax: +1 514 398 8195. Alexander Thiel, Department of Neurology and Neurosurgery, McGill University at Lady Davis Institute for Medical Research, Montreal, Quebec, Canada. Tel.: +1 514 340 8222 2094; fax: +1 514 340 7567.
    • ,
  • Ralf Schirrmacher

      Affiliations

    • McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding authors. Ralf Schirrmacher is to be contacted at Tel.: +1 514 398 1624; fax: +1 514 398 8195. Alexander Thiel, Department of Neurology and Neurosurgery, McGill University at Lady Davis Institute for Medical Research, Montreal, Quebec, Canada. Tel.: +1 514 340 8222 2094; fax: +1 514 340 7567.

Received 24 February 2009 ,Revised 19 May 2009 ,Accepted 27 May 2009.

References 

  1. Maziere M, Prenant C, Sastre J, Crouzel M, Comar D, Hantraye P. 11C-Ro 15-1788 et 11C-flunitrazepam, deux coordinates pour l'etude par tomography par positrons des sites de liaision des benzodiazepines. C R Acad Sci (Paris). 1983;296:871–876
  2. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol. 1995;52:314–317
  3. Heiss WD, Grond M, Thiel A, Ghaemi M, Sobesky J, Rudolf J, et al. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke. 1998;29:454–461
  4. Lucignani G, Panzacchi A, Bosio L, Moresco RM, Ravasi L, Coppa I, et al. GABA A receptor abnormalities in Prader–Willi syndrome assessed with positron emission tomography and [11C]flumazenil. NeuroImage. 2004;22:22–28
  5. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715–720
  6. Litton JE, Neiman J, Pauli S, Farde L, Hindmarsh T, Halldin C, et al. PET analysis of [11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls. Psychiatry Res. 1993;50:1–13
  7. Savic I, Thorell JO, Roland P. [11C]Flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia. 1995;36:1225–1232
  8. Savic I, Svanborg E, Thorell JO. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: a positron emission tomography study. Epilepsia. 1996;37:236–244
  9. Koepp MJ, Labbe C, Richardson MP, Brooks DJ, Van Paesschen W, Cunningham VJ, et al. Regional hippocampal [11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis. Brain. 1997;120:1865–1876
  10. Olsen RW. The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol Cell Biochem. 1981;39:261–279
  11. Mitterhauser M, Wadsak W, Wabnegger L, Mien LK, Tögel S, et al. Biological evaluation of 2′-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol. 2004;31:291–295
  12. Chang YS, Jeong JM, Yoon YH, Kang WJ, Lee SJ, et al. Biological properties of 2′-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. Nucl Med Biol. 2005;32:263–268
  13. Lee JD, Park HJ, Park ES, Kim DG, Rha DW, et al. Assessment of regional GABAA receptor binding using 18F-fluoroflumazenil positron emission tomography in spastic cerebral palsy. NeuroImage. 2007;34:19–25
  14. Moerlein SM, Perlmutter T. Binding of 5-(2′[18F]fluoroethyl) flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography. Eur J Pharmacol. 1992;218:109–115
  15. Gründer G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz HG, Stoeter P, et al. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur J Nucl Med. 2001;28:1463–1470
  16. Leveque P, Sanabria-Bohorquez S, Bol A, De Volder A, Labar D, Van Rijckevorsel K, et al. Quantification of human brain benzodiazepine receptors using [18F]fluoroethylflumazenil: a first report in volunteers and epileptic patients. Eur J Nucl Med Mol Imaging. 2003;30:1630–1636
  17. Sossi V. Cutting-edge brain imaging with positron emission tomography. Neuroimaging Clin N Am. 2007;17:427–440
  18. Wienhard K, Schmand M, Casey ME, Baker K, Bao J, Eriksson L, et al. The ECAT HRRT: performance and first clinical application of the new high research tomograph. IEEE Trans Nucl Sci. 2002;49:104–110
  19. Sossi V, de Jong HWAM, Barker WC, Bloomfield P, Burbar Z, Camborde ML, et al. The second generation HRRT-a multi-centre scanner performance investigation. IEEE Nucl Sci Symp Conf Rec. 2005;4:2195–2199
  20. Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, et al. Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol. 2005;32:109–116
  21. Odano I, Farde L, Savic I, Ciumas C, Krasikova R, Airksinen A, et al. Comparison of central benzodiazepine receptor mapping tracers, [18F]flumazenil and [11C]flumazenil presentation. NeuroImage. 2006;31:P042
  22. Dedeurwaerdre S, Gregoire MC, Vivash L, Roselt P, Binns D, Pham T, et al. Comparison of [18F]fluoroflumazenil and [18F]flumazenil for in vivo PET imaging of GABAA/cBZR density in a rat brain. J Nucl Med. 2007;48:62P
  23. Odano I, Halldin C, Karlsson P, Varrone A, Airaksine AJ, Krasikova RN, et al. [18F]Flumazenil binding to central benzodiazepine receptor studies by PET — Quantitative analysis and comparisons with [11C]flumazenil. NeuroImage. 2009;45:891–902
  24. Klumpers UM, Veltman DJ, Boellaard R, Comans EF, Zuketto C, Yaqub M, et al. Comparison of plasma input and reference tissue models for analysing [11C]flumazenil studies. J Cereb Blood Flow Metab. 2008;28:579–587
  25. Hara T, Kosaka N, Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–199
  26. Heiss WD, Habedank B, Klein JC, Herholz K, Wienhard K, Lenox M, et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med. 2004;45:1811–1815

☆ This work was supported in part by a research grant from the Natural Sciences and Engineering Council Canada (NCERC) to R. Schirrmacher and a Canadian Institutes of Health Research (CIHR) grant (Nr. MOP8444) to A. Thiel.

PII: S0969-8051(09)00149-8

doi: 10.1016/j.nucmedbio.2009.05.008

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 721-727 , October 2009

Article Tools

* Image Usage & Resolution